INVA Stock Overview
Engages in the development and commercialization of pharmaceutical products in the United States and internationally.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 0/6 |
Past Performance | 2/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Innoviva, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$18.55 |
52 Week High | US$19.44 |
52 Week Low | US$12.22 |
Beta | 0.57 |
11 Month Change | 5.52% |
3 Month Change | 17.48% |
1 Year Change | 39.68% |
33 Year Change | 24.58% |
5 Year Change | 69.10% |
Change since IPO | 2.43% |
Recent News & Updates
Recent updates
Benign Growth For Innoviva, Inc. (NASDAQ:INVA) Underpins Its Share Price
Jul 26Innoviva: Potentially Overvalued
Jun 21Why Innoviva's (NASDAQ:INVA) Shaky Earnings Are Just The Beginning Of Its Problems
May 21Here's Why Innoviva (NASDAQ:INVA) Can Manage Its Debt Responsibly
Feb 05Is Innoviva (NASDAQ:INVA) A Risky Investment?
Nov 04Innoviva (NASDAQ:INVA) Seems To Use Debt Quite Sensibly
Mar 02Innoviva Stock? Not Yet. Short Puts? Definitely.
Sep 19Does Innoviva (NASDAQ:INVA) Have A Healthy Balance Sheet?
Sep 19Does Innoviva (NASDAQ:INVA) Have A Healthy Balance Sheet?
Jun 16Continuing To Avoid Innoviva Inc.
Jun 07We Think Innoviva (NASDAQ:INVA) Can Manage Its Debt With Ease
Mar 04Taking Innoviva Winnings Off The Table, Again
Feb 21Innoviva Inc.: Short Puts Are Compelling
Jan 15Is Innoviva (NASDAQ:INVA) A Risky Investment?
Oct 19Taking Profits In Innoviva Inc.
Oct 16Innoviva reports Q1 results
Apr 28These 4 Measures Indicate That Innoviva (NASDAQ:INVA) Is Using Debt Safely
Mar 30Is Weakness In Innoviva, Inc. (NASDAQ:INVA) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
Mar 04Did Innoviva's (NASDAQ:INVA) Share Price Deserve to Gain 36%?
Jan 15These 4 Measures Indicate That Innoviva (NASDAQ:INVA) Is Using Debt Safely
Dec 25Will Weakness in Innoviva, Inc.'s (NASDAQ:INVA) Stock Prove Temporary Given Strong Fundamentals?
Dec 04Innoviva: Only For Short-Term Traders
Nov 04Innoviva reports Q3 results
Oct 28Shareholder Returns
INVA | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 1.0% | 2.3% | 3.1% |
1Y | 39.7% | 17.4% | 25.4% |
Return vs Industry: INVA exceeded the US Pharmaceuticals industry which returned 17.4% over the past year.
Return vs Market: INVA exceeded the US Market which returned 25.4% over the past year.
Price Volatility
INVA volatility | |
---|---|
INVA Average Weekly Movement | 2.8% |
Pharmaceuticals Industry Average Movement | 10.4% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 15.0% |
10% least volatile stocks in US Market | 3.2% |
Stable Share Price: INVA has not had significant price volatility in the past 3 months.
Volatility Over Time: INVA's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1996 | 112 | Pavel Raifeld | www.inva.com |
Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea.
Innoviva, Inc. Fundamentals Summary
INVA fundamental statistics | |
---|---|
Market cap | US$1.16b |
Earnings (TTM) | US$145.42m |
Revenue (TTM) | US$330.50m |
8.0x
P/E Ratio3.5x
P/S RatioIs INVA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
INVA income statement (TTM) | |
---|---|
Revenue | US$330.50m |
Cost of Revenue | US$31.82m |
Gross Profit | US$298.68m |
Other Expenses | US$153.25m |
Earnings | US$145.42m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 2.32 |
Gross Margin | 90.37% |
Net Profit Margin | 44.00% |
Debt/Equity Ratio | 77.8% |
How did INVA perform over the long term?
See historical performance and comparison